SARS-CoV-2 vaccine breakthrough by Omicron and Delta variants: comparative assessments with New York State genomic surveillance data

Alexander C. Keyel, Alexis Russell, Jonathan Plitnick, Jemma V. Rowlands, Eli Rosenberg, Daryl M. Lamson, Kathleen A. McDonough, Kirsten St. George
doi: https://doi.org/10.1101/2022.06.24.22276709

Article Information

doi 
https://doi.org/10.1101/2022.06.24.22276709
History 
  • June 26, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Alexander C. Keyel1,*,
  2. Alexis Russell1,
  3. Jonathan Plitnick1,
  4. Jemma V. Rowlands2,
  5. Eli Rosenberg2,3,
  6. Daryl M. Lamson1,
  7. Kathleen A. McDonough1,2,3 and
  8. Kirsten St. George1,3
  1. 1Wadsworth Center, New York State Department of Health, Albany, NY, United States of America
  2. 2Department of Epidemiology, New York State Department of Health, Albany, NY, United States of America
  3. 3Department of Biomedical Science, University at Albany School of Public Health, State University of New York, Albany, NY, United States of America
  1. ↵*Corresponding Author: Alexander C. Keyel, alexander.keyel{at}health.ny.gov, phone: 518-485-6466, fax: 518-473-1326
Back to top
Posted June 26, 2022.
Download PDF
Data/Code
Email
SARS-CoV-2 vaccine breakthrough by Omicron and Delta variants: comparative assessments with New York State genomic surveillance data
Alexander C. Keyel, Alexis Russell, Jonathan Plitnick, Jemma V. Rowlands, Eli Rosenberg, Daryl M. Lamson, Kathleen A. McDonough, Kirsten St. George
medRxiv 2022.06.24.22276709; doi: https://doi.org/10.1101/2022.06.24.22276709
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area